Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Debt to Equity (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Debt to Equity for 4 consecutive years, with $1.45 as the latest value for Q4 2025.

  • Quarterly Debt to Equity fell 54.35% to $1.45 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.45 through Dec 2025, down 54.35% year-over-year, with the annual reading at $1.45 for FY2025, 54.35% down from the prior year.
  • Debt to Equity hit $1.45 in Q4 2025 for Axsome Therapeutics, down from $2.55 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $6.54 in Q2 2022 to a low of $0.64 in Q3 2022.
  • Historically, Debt to Equity has averaged $2.1 across 4 years, with a median of $1.63 in 2024.
  • Biggest five-year swings in Debt to Equity: crashed 89.96% in 2023 and later soared 228.12% in 2024.
  • Year by year, Debt to Equity stood at $0.91 in 2022, then grew by 5.66% to $0.97 in 2023, then surged by 228.12% to $3.17 in 2024, then plummeted by 54.35% to $1.45 in 2025.
  • Business Quant data shows Debt to Equity for AXSM at $1.45 in Q4 2025, $2.55 in Q3 2025, and $2.57 in Q2 2025.